Mysterious Fog in the US , Canada and UK: A dense, eerie fog with a "burning chemical-like smell" has spooked a good part of North America and parts of the United Kingdom and Canada. With social media amplifying all concerns, this phenomenon has sparked attention across all social media platforms. However, at the heart of this mysterious fog are a conjunction of natural events, social psychology, and environmental conditions that culminated in all the conspiracy theories and public health fears. Here's a closer look at the mysterious fog, its potential causes, and the societal response it has triggered.

Fog that Feeds Fear

The first reports of this "mysterious fog" came in from Florida where a resident said that they experienced respiratory symptoms, feverish warmth, and stomach cramps after contact with the fog. Similar stories started flooding social media, and within a day or two, a sinister force seemed to sweep across the United States, Canada, and parts of the UK. From Texas to Minnesota, people reported weird odors and health issues that they thought were linked to this bizarre atmospheric event.

Some witnesses were said to see "white particles" swirling through the air; theories ranged from a chemical attack or experimental weapon to drone-related chemical dispersals and references to historical military experiments, such as the infamous 1950s "Operation Sea-Spray."

Fuel to the fire were added when videos and posts, hundreds of thousands in number, began circulating on social media sites like TikTok and X (formerly Twitter) speculating on the origin of the fog. Hashtags like #ToxicFog went trending for days. Hysteria created a self-reinforcing loop in which every post spurred further scrutiny and fear.

Scientific Explanation of the Dense Mysterious Fog

1. What is Fog?

Fog is essentially a low-lying cloud formed when the air temperature cools to its dew point, causing water vapor to condense into tiny droplets or ice crystals. Several types of fog—advection fog, radiation fog, and valley fog—can form depending on conditions such as warm, moist air moving over cooler land or when temperatures plummet rapidly under clear skies.

2. Why the Chemical Smell?

Such chemical-like smell as reported during the occurrence of fog events is sometimes attributed to air pollution. It acts like a sponge, where it absorbs these pollutants, which include sulfur dioxide and nitrogen oxides, among others, that emit from industries. This mixture, therefore, leads to a stench that could be mistaken as unnatural or even toxic.

Also Read: Health Concerns Rise As US, Canada, and UK Come Under The Blanket Of Thick, Dense, Toxic Fog

3. What are the Health Concerns?

High moisture levels from fog can significantly exacerbate symptoms related to respiration, but especially in already predisposed asthmatics and allergy patients. The connection of these symptoms with actual fever, stomach cramps, and puffy eyes is too remote. Experts assume that the irritating effects of entrapped pollutants trapped in fog tend to affect more the eyes and throat rather than the rest of the body affected by some report.

Psychological Effects of Mass Panic Caused by Social Media

Social media amplified a natural weather event into a health epidemic. It made the personal experience of individuals become a cause for fear and speculation, a domino effect.

According to psychologists, this is a concept of selective perception, wherein once people's attention is drawn to environmental anomalies, they begin to notice them. This mirrors earlier panics, such as the Seattle windshield pitting panic of 1954. Then, atomic bomb testing caused fear in many and started to have people looking at their windshields for small marks that they had not seen before. Likewise, postings on the strangeness of the fog probably increased public awareness and suspicion, with people looking to attach unrelated symptoms to the phenomenon.

The fog hysteria shares a commonality with other instances of mass panic, such as the "drone sightings" of recent years or the Cold War-era fears of biological warfare.

Also Read: Mysterious Fog Is Making Americans Sick

These events underscore how fear can cloud judgment, especially when amplified by social media and sensationalist headlines. While historical cases, such as "Operation Sea-Spray," offer concrete evidence of the existence of unethical experiments, the jump from a natural weather condition to theories of chemical attacks exemplifies a more modern trend of connecting unrelated dots, all wonderfully seeded in distrust and anxiety.

Despite the swirling rumors, meteorologists and scientists are in agreement that the mysterious fog is not as alarming as it seems. It is well known that fog traps and amplifies pollutants, especially in urban and industrial regions. Moreover, winter months are the most conducive for fog formation, so its recent prevalence is unsurprising.

On the other hand, environmentalists advise that the fog should wake everyone up to increased levels of pollution. The reported odors and health irritations could be just symptoms of far deeper systemic issues like industrial emissions and lack of control over air quality.

The authorities must be transparent in their communication to combat misinformation and allay public fears. Governments and environmental agencies must provide timely updates on weather phenomena, air quality, and health risks. Initiatives like real-time pollutant tracking and public education campaigns can help demystify natural occurrences while addressing valid environmental concerns.

The mysterious Canada fog is a compelling case study in how environmental events intersect with psychology and societal dynamics. While rooted in natural phenomena, the fog became a vessel for collective fears, amplified by modern technology and historical anxieties.

In this information era where communication occurs at an almost lightning pace, the fog becomes a metaphor that reminds everyone about scientific literacy, environmental responsibility, and an effective balance when considering public concern. Whether perceived as a marvel of nature or as a tale that serves to teach, it left a very powerful mark in people's minds.

In a world first, scientists have administered AI-designed viruses to a human patient to treat a serious antibiotic-resistant bacterial infection. The experimental treatment marks a milestone in the development of personalized therapies that use artificial intelligence (AI) to design viruses capable of targeting drug-resistant bacteria.

California-based AI startup Radical Numerics announced the development in a blog post, saying a patient with a serious bacterial infection received an experimental treatment containing viruses generated by its AI model, Omnii-1.

How AI Helped Design the Viruses

Also read: AI Creates 16 Viruses To Kill Drug-Resistant E. coli, Raises Biosafety Concerns

The treatment uses bacteriophages, or phages, which are viruses that infect and kill bacteria. Phage therapy is being explored as an alternative when antibiotics fail, particularly in drug-resistant infections.

However, identifying phages that can effectively target the specific bacteria causing an individual patient's infection remains a major challenge.

Antibiotic resistance is a growing global health threat. A 2024 study published in The Lancet projected that bacterial antimicrobial resistance could directly cause 39.1 million deaths globally between 2025 and 2050.

Radical Numerics said it trained Omnii-1, its multimodal genome language model, to address the challenge of identifying and designing effective phages.

"We trained Omnii-1, our multimodal genome language model, to help bridge this gap. We demonstrate that it can generate viable phages, prioritize variants, and predict phage-host interactions," the company said.

"In the world's first clinical use of AI-generated phages, Omnii-1 designs were administered to a human patient under compassionate use," it added.

How Did the AI-Designed Phage Treatment Work?

Read More: Anthropic Says Claude Blocked Bird Flu, Chikungunya Research: How AI Could Enable Biological Misuse

According to the company, researchers tested the AI-designed viruses against bacteria obtained from the patient before administering the treatment. The resulting phage cocktail eliminated the patient's antibiotic-resistant bacterial sample in laboratory testing.

The treatment was administered under an authorized, physician-led compassionate-use pathway. Compassionate use allows patients with serious conditions to access investigational treatments outside clinical trials when satisfactory alternatives are unavailable, subject to regulatory authorization and appropriate oversight.

The report has not been peer-reviewed or published in a scientific journal. Company officials said the trial had been authorized by the Food and Drug Administration, the New York Times reported.

The company has not disclosed the patient's diagnosis, clinical course or treatment outcome, citing privacy concerns. It is therefore unclear whether the treatment successfully cleared the infection.

Eric Nguyen, chief executive officer of Radical Numerics, said the company was prioritizing patient confidentiality and intended to publish its findings through peer-reviewed research.

"We intend to publish our scientific findings through peer-reviewed research, with any future disclosure of clinical details subject to appropriate consent," he added.

The company said making phage therapy accessible to more patients would require reliable workflows for designing effective phages against individual bacterial infections.

Previous Research Used AI to Design Bacteria-Killing Viruses

The development comes amid growing interest in using AI to accelerate medical research, including the design of new biological therapies.

In August 2026, researchers at Stanford University and the Arc Institute announced that they had used AI to design previously unseen bacteriophages capable of killing E. coli bacteria in laboratory experiments.

Of nearly 300 AI-designed phages synthesized and tested, 16 produced functional viruses. However, these experiments were conducted in bacteria and did not involve human patients.

The Radical Numerics development goes a step further by reporting the clinical administration of AI-designed phages to a human patient.

The share of US children aged 5–17 who had ever received an attention-deficit/hyperactivity disorder (ADHD) diagnosis increased from 9.9% in 2019 to 13.8% in 2025, according to new CDC data.

Nearly 1 in 7 children and adolescents aged 5–17 in the US have received an ADHD diagnosis, according to a QuickStats report published in the CDC's latest Morbidity and Mortality Weekly Report (MMWR).

The National Center for Health Statistics (NCHS) found that the percentage of children who had ever been diagnosed with ADHD increased by 3.9 percentage points over the seven years, representing a relative rise of approximately 39%.

More boys received the diagnoses than girls throughout the period, although the trends fluctuated from year to year.

ADHD Diagnoses Among US Children: Trends From 2019 to 2025

Also read: ADHD Linked To 71% Higher Risk Of Death; Suicide And Injuries Among Top Concerns

According to the CDC data, the percentage of US children and adolescents aged 5–17 who had ever received an ADHD diagnosis rose from 9.9% in 2019 to 11.6% in 2020. It dipped to 10.8% in 2021 before increasing to 11.5% in 2022.

The figure climbed to 13.4% in 2023, 13.6% in 2024 and 13.8% in 2025.

Among boys, the percentage increased from 13.2% in 2019 to 17.5% in 2025, reaching a high of 17.6% in 2024.

Among girls, it rose from 6.5% in 2019 to 9.9% in 2025, although it dipped from 9.9% in 2023 to 9.3% in 2024.

The estimates are based on household interviews with a sample of the civilian, noninstitutionalised US population. The survey considered children to have an ADHD diagnosis if a parent or respondent answered yes to whether a doctor or health professional had ever told them the child had ADHD or attention-deficit disorder (ADD).

What Is ADHD?

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that affects attention, executive function, impulse control and activity levels. It typically begins in childhood, with symptoms appearing before age 12, and can persist into adulthood.

Read More: Attention Deficit May Be The Wrong Way To Understand ADHD, Says US Psychiatrist

What Are the Symptoms of ADHD?

According to the National Institute of Mental Health (NIMH), ADHD symptoms fall into two primary categories:

• Inattention: Difficulty sustaining focus, missing details, making careless mistakes, forgetfulness in daily routines and struggling to stay organised.
• Hyperactivity and impulsivity: Fidgeting, excessive talking, restlessness, interrupting others and acting without thinking. In adults, hyperactivity may also manifest as internal restlessness.

AAP Guidance on ADHD Evaluation and Treatment in Children

The American Academy of Pediatrics (AAP) 2019 clinical practice guideline recommends that primary care clinicians initiate an ADHD evaluation for children and adolescents aged 4–18 who present with academic or behavioural problems and symptoms of inattention, hyperactivity or impulsivity.

The guideline recommends assessing children using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria, based on information from parents, teachers and other school personnel.

It also calls for screening for coexisting emotional, behavioural, developmental and physical conditions.

For preschool-aged children, parent training in behaviour management is recommended as a first-line approach.

For school-aged children and adolescents, the AAP recommends FDA-approved medication alongside behavioural and school-based interventions. It also emphasises managing ADHD as a chronic condition, with ongoing monitoring and follow-up.

A patient has received a pioneering stem cell treatment for Parkinson's disease in Japan, marking a world first following the therapy's conditional approval in the country.

Developed by Japanese drugmaker Sumitomo Pharma in collaboration with Dr Jun Takahashi at Kyoto University, the therapy, Amchepry (also known as raguneprocel), is the world's first induced pluripotent stem cell (iPSC)-based treatment for Parkinson's disease. It received conditional approval in March 2026 following successful clinical trial results.

The first transplant was performed at Kyoto University Hospital in October, the company said on Friday in an earnings press release, without providing further details, AFP reported.

How Does the Parkinson's Stem Cell Treatment Work?

Also read: Parkinson’s at 40: Why Younger Adults Are Being Diagnosed Earlier Than Before

The treatment uses iPSCs obtained from healthy donors, which are developed into precursors of dopamine-producing neurons and transplanted into the brain to replace cells lost due to Parkinson's disease.

iPSCs are created by reprogramming mature, specialised cells to return to an earlier state, allowing them to develop into different cell types.

Stem cell therapy, also known as regenerative medicine, uses stem cells or their derivatives to repair or replace damaged tissues.

What Did the Clinical Trial Find?

During the clinical trial, seven patients aged between 50 and 69 received implants of either five million or 10 million cells on both sides of the brain.

The patients were monitored for two years. Researchers found no major adverse effects, while four participants showed improvements in their symptoms, AFP reported.

Sumitomo Pharma said it plans to perform transplants in 20 to 30 patients by March 2029. The company is also conducting a clinical trial of the treatment in the United States.

The therapy will receive full approval in Japan if its safety and effectiveness are confirmed over the next seven years, according to local media reports.

Read More: Parkinson’s Disease: Women Have More Motor Complications, Depression

Japan Also Approves Stem Cell Therapy for Heart Failure

The announcement comes a month after a hospital in Osaka performed the world's first surgery using sheets of heart muscle cells derived from iPSCs.

The sheets are designed to promote new blood vessel formation and help restore heart function. The treatment also received conditional approval in Japan in March.

Conditional approval allows these therapies to be used clinically while additional data on their safety and effectiveness are collected.

What Is Parkinson's Disease?

Parkinson's disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing brain cells. It primarily affects people over the age of 60 and is estimated to affect more than 10 million people worldwide, according to the Parkinson's Foundation.

Dopamine plays an important role in controlling movement. Its loss can cause symptoms such as:

• Tremors, often beginning in one hand, foot or the jaw.
• Muscle stiffness and slowed movement.
• Difficulty maintaining balance, increasing the risk of falls.
• Changes in speech, including softer or slurred speech.
• Difficulty swallowing.

The disease can also cause cognitive decline, depression and anxiety. Currently available treatments help manage symptoms but do not stop or reverse disease progression, according to the Parkinson's Foundation.